Company (Symbol)* | University/ Non-Profit [Scientist] | Type Of Agreement | Product Area | Details (Month) |
Adenosine Therapeutics LLC* | University of Virginia Patent Foundation and the National Institutes of Health [Kenneth Jacobson (NIH) and Joel Linden (U.Va.)] | License | Covers approximately 50 new A2B adenosine receptor antagonist compounds that are anilide derivatives of 8-phenyxanthines and are structurally related to theophylline, an approved asthma drug | ND (6/00) |
Advanced Tissue Sciences Inc. (ATIS) | University of Washington and the National Institutes of Health | Research collaboration and grant | Development of tissue-engineered functional human heart tissue; initial focus is on culturing thick patches of cardiac muscle that could be grafted onto damaged hearts | NIH is providing a $10M grant over five years; other participants are the Hope Heart Institute in Seattle, Advanced Polymer Systems and the University of Toronto; project timetable is 10 years, and the group plans to apply for renewed funding at the end of five-year grant term (5/00) |
Affymetrix Inc. (AFFX) | AmDeC (organization of medical schools, academic health centers and research institutions in the New York area) | Technology access | Participating institutions gain access to Affymetrix standard and custom GeneChip arrays, instrumentation and software to monitor gene expression | Under Affymetrix' Academic Access Preferred program, participants receive discounts (4/00) |
Affymetrix Inc. (AFFX) | Queensland University of Technology (Australia) | Patent rights | Technology for detecting single nucleotide polymorphisms | Queensland sold the patent for an undisclosed sum (3/00) |
Allergan (NYSE:AGN) | Centre for Applied Microbiology & Research (CAMR;UK) | License and research collaboration | Collaboration centers on CAMR's neurotoxin-based technology that targets acute and chronic pain | CAMR could receive up to #30.25M (US$20.5M) in research fees, technology fees and milestone payments; Allergan will have exclusive rights to commercialize the technology (5/00) |
Amarillo Biosciences Inc.(OTC BB: AMAR) | Molecular Medicine Research Institute [Ed Amento] | Research collaboration | Development of a low-dose formulation of interferon-gamma based on patent application on which Amento and Amarillo's CEO and president are co-inventors | ND (4/00) |
Aradigm Corp. (ARDM) | University of California at San Francisco [Jeanine Wiener-Kronish] | Research collaboration | Evaluation of Aradigm's AERx pulmonary delivery system for delivering non-viral gene vectors by inhalation | The National Institutes of Health is providing funding (4/00) |
Ariad Pharmaceuticals Inc. (ARIA) | University of Washington [C. Anthony Blau] | License and expansion of research collaboration | License to two patent applications covering methods for controlling growth and differentiation of stem cells and other progenitor cells using Ariad's Argent technology; expansion of research collaboration to develop stem cell products | The patent license is exclusive; Ariad also receives rights to all intellectual property and inventions made using its technology as part of the collaboration (4/00) |
Aurora Biosciences Corp. (ABSC) | Families of Spinal Muscular Atrophy | Research collaboration | Aurora will develop screen-based assays to mimic a functional defect in spinal muscular atrophy and will screen compounds, perform follow-up on hits and collaborate with academic researchers on animal testing | FSMA will fund research (3/00) |
Aurora Biosciences Corp. (ABSC) | Cystic Fibrosis Foundation | Research collaboration | Aurora will use its genomics and screening platform to discover targets, develop assays and discover and optimize potential lead compounds; collaboration includes development of an assay for, and screening of, the cystic fibrosis transmembrane conductance regulator (CFTR) protein | The foundation will fund the initiative through technology access fees, and fees for ongoing scientific support; Aurora could receive $30M in committed funding and progress payments, before clinical milestones; Aurora and the foundation also agreed to co-commercialize promising candidates and share revenues on any marketed products (5/00) |
Biacore International AB (Sweden; SSE:BCOR) | Huntsman Cancer Institute at the University of Utah [David Myszka] | Research collaboration | HCI will evaluate Biacore's new prototype high-performance system in analyzing the binding of small molecules to defined drug targets and in characterization applications | Myszka will lead a team that will test the system by studying the binding of small molecules to human serum albumin (4/00) |
Celera Genomics (NYSE:CRA) | City of Hope Cancer Center | Research collaboration | Discovery of genetic polymorphisms associated with breast cancer | Celera retains rights to use all the information generated in its database products; intellectual property to be jointly owned by Celera and City of Hope (3/00) |
Celera Genomics (NYSE:CRA) | Vanderbilt University | Database access | Vanderbilt gains a subscription to four Celera database products, becoming the first subscriber to access Celera's databases through the Celera Discovery System on the World Wide Web | Five-year agreement; academic subscription rates depend on nature of subscription, institution size, and the number of concurrent users (5/00) |
Celgene Corp. (CELG) | National Cancer Institute | Cooperative research and development agreement | Preclinical and clinical development of Celgene's IMiDs, a group of thalidomide analogues | Celgene signed a letter of intent to enter a CRADA with NCI; goal of the five-year program will be preclinical and clinical evaluation of lead compound (CDC-501) and other compounds from the IMiD family (6/00) |
Cel-Sci Corp. (AMEX:CVM) | South African government | License | Government gains license to test and use Cel-Sci's HGP-30W AIDS Vaccine/TD> |
The license is free; Cel-Sci requested the South African government agree to a joint time schedule for development and that it make the results of its studies available to Cel-Sci for any eventual marketing of of the vaccine in other countries (4/00) |
Cel-Sci Corp. (AMEX:CVM) | National Cancer Institute [Jay Berzofsky] | Cooperative research and development agreement | Testing of NCI's HIV peptide epitopes and Cel-Sci's LEAPS technology for peptide delivery; goal is to develop an improved HIV vaccine for use in treatment or prevention | Cel-Sci and NCI will jointly test vaccines (6/00) |
Celsion Corp. (OTC BB: CLN) | Memorial Sloan-Kettering Cancer Center [Gloria Li] | License | Heat-activated gene therapy technology for treating cancer; proposed treatment combines Celsion's focused heat equipment with a heat-sensitive biological modifier developed at MSK and is intended to improve the performance of conventional radiation and chemotherapy | Agreement grants Celsion worldwide exclusive commercial rights to the technology (5/00) |
Chiron Corp. (CHIR) | National Institute of Public Health of Norway | Development and commercialization agreement | Development of meningitis B and combination meningitis B and C vaccines; NIPH has developed a meningitis B vaccine; the combination product will merge that vaccine with Chiron's meningococcal C conjugate vaccine Menjugate | Chiron has exclusive worldwide marketing and manufacturing rights outside Norway; NIPH has rights within its home country (5/00) |
CuraGen Corp. (CRGN) | Berkeley Drosophila Genome Project | Research collaboration | Development of the first protein interaction map of the Drosophila melanogaster genome | Data expected to be released to the public later this year (3/00) |
CytoGenix Inc. (CYGX) | Baylor College of Medicine at the Texas Medical Center in Houston [Steve Welty] | Sponsored research agreement | Baylor researchers will use CytoGenix's technology for the intracellular synthesis of single-stranded DNA (ssDNA) in a project to test enhancement of expression of anti-inflammatory oligodeoxyucleotides in tissue cultures of A549 cells (a type of lung cell) using an Isis Pharmaceuticals antisense molecule (Isis 2302) inserted in a Cytogenix ssDNA expression systems | If project succeeds, the next step will be testing in mice (6/00) |
Digene Corp. (DIGE) | Institut Pasteur (France) | License | License is for U.S. patent No. 5,981,173, covering the genetic sequence of human papilloma virus types 68 and 70 and the detection of HPV 68 and 70 using DNA testing methods | Digene gains an exclusive worldwide license in the field of HPV in vitro human diagnostics and in vitro preclinical and clinical diagnostic testing for vaccine and therapeutic discovery and development (4/00) |
Digital Gene Technologies Inc.* | Mayo Foundation for Medical Education and Research [Ralf Janknecht] | Research collaboration | Use of Digital Gene's TOGA gene expression profiling technology (TOtal Gene expression Analysis) to investigate the role of the transcription factor ER81 in the formation of a variety of tumors | Agreement falls under Digital Gene's academic collaboration program, which provides access to TOGA while reserving commercial opportunities for Digital Gene (4/00) |
DoubleTwist Inc.* | Biotechnology Industry Organization | Internet development agreement | Construction of a comprehensive, independent Internet portal with access to e-commerce providers, scientific and business news, events and jobs; users would include BIO members, academic researchers and others interested in the life sciences | Entities signed a letter of intent for the project; they expect to enter multiple, non-exclusive partnerships with independent and third-party service providers; BIO members will receive discounts on services offered through the portal (5/00) |
Exelixis Inc. (EXEL) | National Cancer Institute | Cooperative research and development agreement | Exelixis will use model system genetics technology to identify the mechanism of action for NCI compounds | Three-year collaboration; Exelixis will benefit from identifying targets, which it can use to find other active compounds (5/00) |
Genome Therapeutics Corp. (GENE) | Northeastern University [Roger Giese] | Option and sponsored research agreement | Development of Northeastern's mass-spectrometry-based technology for detecting single nucleotide polymorphisms | Genome Therapeutics secured rights to obtain worldwide exclusive access to the technology and will fund a research program at Northeastern to develop electrophore mass tags as DNA probe labels (6/00) |
ICAgen Inc.* | Children's Hospital Boston [Carlo Brugnara and Wayne Lencer] and Beth Israel Deaconess Medical Center [Seth Alper] | License and research collaboration | Patents and technologies for medical conditions including hematological, immunological and gastrointestinal disorders; initial focus is on sickle cell disease | ND (3/00) |
ID Biomedical Corp. (Canada; IDBE) | University of British Columbia [Brett Finlay] | License | UBC technology for the oral delivery of vaccines and drugs, as well as the E. coli vaccine that has been the subject of an ongoing collaboration between the parties | ID gains a worldwide exclusive license to the technology and definite licensing terms for the E. coli vaccine (4/00) |
Idec Pharmaceuticals Corp. (IDPH) | National Cancer Institute | License | Use of PAGE-4 plasmid DNA and PAGE-4 protein for the development and commercialization of a therapeutic vaccine to treat prostate cancer | Idec gains an exclusive worldwide license under agreement, which was preceded by a cooperative research and development agreement (4/00) |
Idec Pharmaceuticals Corp. (IDPH) | University of Iowa Research Foundation | License | Use of a prostate-specific, surface-reactive monoclonal antibody (5E10) for evaluation as a potential therapy for prostate carcinoma | Idec gains an exclusive worldwide license (4/00) |
Idun Pharmaceuticals* | University of Texas Southwestern Medical Center at Dallas [Xiadong Wang] | License | Use of Apaf-1 gene, which encodes a protein critical to apoptosis | Idun gains exclusive rights (4/00) |
ImClone Systems Inc. (IMCL) | Princeton University [Ihor Lemischka], and universities of Kentucky and Pennsylvania | Research collaboration | Program to create a comprehensive database to identify all genes responsible for the proliferation, self-renewal and differentiation of hematopoietic stem cells | ImClone will sponsor and participate in research, and will have the exclusive right to negotiate licenses to the complete gene sequences discovered through the research and to the underlying expressed sequence tags (6/00) |
Immtech International Inc. (IMMT) | The London School of Hygiene and Tropical Medicine [Simon Croft], Georgia State University [David Boykin], the University of North Carolina [J. Ed Hall], and the U.S. Military Research Institute | Establishment of research consortium | Development of new treatments for Leishmaniasis | Immtech will fund animal testing at Croft's lab; further financial details ND (4/00) |
Incyte Genomics Inc. (INCY) | The National Institutes of Health | Contract research | Incyte will sequence DNA for the NIH's Mammalian Gene Collection as part of the NIH's effort to create a public domain set of full-length expressed human and mouse genes | Incyte will provide customized sequencing services under a contract; all data will be added to dbEST, a public respository for cDNA; all clones will be made available through the IMAGE consortium (5/00) |
Incyte Genomics Inc. (INCY) | The Roy Castle International Centre for Lung Cancer Research (UK) | Research collaboration | Program to study the role of genes in the prevention, diagnosis and treatment of lung cancer; Incyte will provide access to human genome database and RCIC will provide lung cancer samples, which Incyte will analyze for gene expression; data will be incorporated in the company's LifeExpress database | Intellectual property will be jointly owned and available for licensing through Incyte (6/00) |
Isis Pharmaceuticals (ISIP) | University of Washington School of Medicine | Research consortium | Isis joined the university's Cell Systems Initiative, whose mission is to understand in detail how cellular systems work; Isis will contribute expertise in gene functionalization and target inhibition using antisense; Isis' Ibis subsidiary brings RNA expertise | Three-year agreement in which Isis will actively participate and contribute funding and technologies in functional genomics and target validation and bioinformatics; consortium includes other academic and industry participants (3/00) |
Ivax Corp. (AMEX:IVX) | Center for Blood Research Inc. (affiliate of Harvard Medical School) and the center's subsidiary, CBR Laboratories Inc. | License option | Development of a recombinant monocyte/neutrophil elastase inhibitor for cystic fibrosis, to be dedelivered via an Ivax inhalation device | Ivax will negotiate for a worldwide exclusive license; CBR Laboratories will continue preclinical work (funded in part by grants from the Cystic Fibrosis Foundation), and Ivax will develop a formulation of the compound for delivery by inhalation (5/00) |
Life Technologies Inc. (OTC BB: LTEK) | Genoscope (France) | Research collaboration | Development of a large collection of full-length human genes to be made available to the research community; Life will provide full-length cDNA library and normalization technology, and Genoscope will provide high-capacity automated sequencing capability | Sequencing data to be made public; Life has rights to distribute full-length cDNA clones on a worldwide basis (5/00) |
MediGene AG* (Germany) | Friedrich-Alexander-University-Erlangen-Nurnberg (Germany) [Thomas Eschenhagen] | License | Use of the "in vitro heart," a 3-dimensional matrix technology used to validate a gene's biological role and perform drug screening in a life-like surrounding | MediGene in-licensed all rights; Eschenhagen receives up-front payments and license fees (4/00) |
Micrologix Biotech Inc. (Canada; TSE:MBI) | Harbor-UCLA Research and Education Institute [Michael Yeaman] | Licensing and development agreement | Development of a Harbor-UCLA anti-microbial peptide technology based on a class of proteins produced by platelets; deal covers the technology platform as well as a collaboration to discover and optimize compounds | Micrologix gains worldwide exclusive rights to the technology and will pay a license fee, plus milestones and royalties; in conjunction with the license, the entities entered a multi-year collaboration related to the discovery, design and optimization of platelet-derived compounds for treatment of infectious diseases and other applications; Micrologix will fund the program and have exclusive rights to inventions arising from the research (6/00) |
Molecular Dynamics (subsidiary of Amersham Pharmacia Biotech, which is jointly owned by Nycomed Amersham plc [UK; NYSE:NYE] and Pharmacia Corp. [NYSE:PHA]) | The Zoological Society of San Diego's Center for Reproduction of Endangered Species | Research collaboration | Molecular Dynamics will use the society's Frozen Zoo DNA sample collection to sequence mitochondrial DNA of endangered species and build a data library for zoologists and conservation biologists | ND (5/00) |
MPB Cologne GmbH* (Germany) | The European Molecular Biology Laboratory | License | EMBL's recombinase-ligand binding domain technology for application in plant biotechnology; the technology presets a gene switch for activation or inactivation at certain times during an organism's life cycle | MPB obtained a worldwide exclusive license and is entitled to grant sublicenses to partners and clients (5/00) |
Nanogen Inc. (NGEN) | Saint Louis University | License | Method for detecting genetic diseases and gene sequence variations by single nucleotide primer extension | Non-exclusive agreement (3/00) |
Novavax Inc. (AMEX:NOX) | California Pacific Medical Center and St. Mary's Medical Center [Li-Xi Yang] | Licensing option | Novavax will evaluate a series of metronidazole analogs developed by Yang in combination with the company's Novasome and emulsion technologies; metronidazole has been used to treat bacterial infections | Novavax will evaluate the compounds for six months; further details ND (5/00) |
Oxford BioMedica plc (UK; LSE:OXB) | Massachusetts General Hospital, Boston University and the Dana-Farber Cancer Institute | License | Use of the family of cytochrome P450 enzymes in cancer gene therapy; the cytochrome P450 gene CYP2B6 is the therapeutic gene used in MetXia-P450, Oxford's first gene therapy product (in Phase I/II trials) | Oxford BioMedica gains exclusive access and will pay an up-front fee, milestones and royalties on sales; under a separate agreement, the three non-profit partners made an equity investment in Oxford, purchasing 0.5M shares (5/00) |
Oxford BioMedica plc (UK; LSE:OXB) | UK Microbiological Research Authority Centre for Applied Microbiology and Research | License | Series of genes isolated by CAMR scientists that encode nitroreductases, enzymes that can be used in enzyme/prodrug activation strategies | Oxford BioMedica gains exclusive rights and will provide research funding, an up-front fee, milestones and royalties on future sales (5/00) |
Panacea Pharmaceuticals Inc.* | Rhode Island Hospital/Brown University | License and research collaboration | Human aspartyl beta-hydoxylase, the over-expression of which is associated with the transformation of normal cells to malignant tumors | Panacea has exclusive worldwide rights for the use of HAAH in human cancers, plus rights to future developments under the collaborative research agreement (6/00) |
PPGx Inc. (joint venture of PPD Inc. [PPDI] and Axys Pharmaceuticals Inc. [AXPH]) | St. Jude Children's Research Hospital | License | Test for mutations in the thiopurine S-methyl transferase gene, which are linked to possible life-threatening reactions to common anticancer drugs | PPGx gains an exclusive worldwide license to the test and will market it through pharmacogenomic testing laboratories; PPGx also has the right to issue sublicenses (4/00) |
Protarga Inc.* | National Cancer Institute [Edward Sausville] | Cooperative research and development agreement | Development of new drugs by the attachment of promising NCI cancer agents to Protarga's fatty acid vectors | NCI will conduct preclinical testing; Protarga has the exclusive right to license patents resulting from the collaboration (4/00) |
Senetek plc (UK; SNTKY) | Tel Aviv University-Ramot [Illana Gozes] and the Weizmann Institute of Science-Yeda [Mati Fridkin] | Research and development collaboration | Use of 17 patented analogs of vasoactive intestinal peptide for the topical treatment of sexual dysfunction; one compound (stearyl-norleucine-VIP) is ready to enter clinical trials | Senetek gains exclusive rights to the compounds; Gozes and Fridkin will direct clinical research (5/00) |
Senomyx Inc.* (formerly Ambryx Inc.) | Johns Hopkins University [Solomon Snyder] | License | Use of technology that identifies new forms of an amiloride-sensitive sodium channel and new possible methods of identifying substances that stimulate or block salty taste perception | ND (5/00) |
Senomyx Inc.* (formerly Ambryx Inc.) | University of California | License | Family of candidate taste receptors called T2Rs and related technologies; the receptors are G protein-coupled receptors | Agreement also covers two candidate taste receptors belonging to the T1R family and other molecules involved in the biology of taste, to which Senomyx had earlier acquired an exclusive option (3/00) |
Sequenom Inc. (SQNM) | National Institute of Diabetes and Digestive and Kidney Diseases | Research collaboration | Sequenom will analyze NIDDK DNA samples for single nucleotide polymorphisms that correlate to Type II diabetes | Contract research agreement expands existing relationship between Sequenom and the National Institutes of Health, with current projects generating $0.5M this year (6/00) |
Siga Technologies Inc. (SIGA) | Oregon State University | License | Chlamydia vaccine technology in animal testing; uses a family of proteins involved in critical intra-cellular step in infection process | Siga exercised an option to acquire exclusive rights (3/00) |
SignalGene (Canada; TSE: SGI) | National Research Council of Canada's Institute for Biological Sciences [Roy Walker] | Research collaboration | SignalGene will seek new drug targets by analyzing gene expression patterns in human pathology samples and biological models of neurodegeneration prepared for or developed by NRC researchers | Each party will fund its share of the work and share in commercialization (5/00) |
Sonus Pharmaceuticals Inc. (SNUS) | State University of New York at Buffalo | Research collaboration | Use of Sonus' perfluoropentane emulsion technology to develop blood substitute products for intravascular oxygen delivery | SUNY will lead efforts and will be responsible for licensing to third parties (4/00) |
SuperGen Inc. (SUPG) | National Cancer Institute | Cooperative research and development agreement | NCI will sponsor clinical trials of SuperGen's decitabine in solid tumors and hematological malignancies; studies also will examine the role of the product's mechanism of action in gene regulation and the regulation of growth and redifferentiation of malignant cells | SuperGen will provide clinical trial supplies of decitabine and conduct its own Phase III study in myelodysplastic syndrome and Phase II in non-small-cell lung cancer (5/00) |
SuperGen Inc. (SUPG) | Albert Einstein College of Medicine and Montefiore Hospital [Robert Bases] | License | SuperGen acquired rights to lucanthone, a clinical-stage topoisomerase II inhibititor that has shown promising radio-sensitizing activity for cancer treatment | SuperGen acquired the rights from Bases; details ND (5/00) |
Symyx Technologies Inc. (SMMX) | Institut fuer Microtechnik Mainz GmbH (Germany) | Development collaboration | Development of micro-fluidic and micro-electro-chemical systems to expand and enhance Symyx's platforms for the rapid discovery of new materials; objective is to create microreactors on chips | Exclusive collaboration for the two-year term of the agreement (5/00) |
Tm Bioscience (Canada; CDNX: TMC) | Ontario Cancer Institute Microarray Facility at Prince Margaret Hospital (Canada) [Neil Winegarden] | Development and technical services agreement | Development of the Tm-ONE DNA biochip technology access platform | OCI will provide Tm with biochip development and technical services (4/00) |
Vernalis Group plc (UK; LSE:VER; formerly Vanguard Medica) | Wolfson Institute for Biomedical Research (UK) | Research collaboration | Discovery of sodium channel blockers as treatments for neuropathic pain | Expansion of 1998 agreement that focused on stroke; Vernalis will be responsible for commercialization; agreement allows for Vernalis to pursue additional indications using the technology (3/00) |
Vertex Pharmaceuticals Inc. (VRTX) | Harvard Medical School | Research collaboration | Use of Harvard genomic and proteomic information to accelerate small-molecule drug discovery; Vertex will use the information as part of chemogenomics discovery effort, which seeks to design multiple drugs in parallel based on structurally similar targets in gene families | Vertex is the first to join Harvard Institute of Proteomics' consortium supporting development of repository of full-length human genes with the goal of developing tools to analyze expressed proteins and interactions; Vertex will have comprehensive access to the institute's genomic and proteomic resources and technologies; financial terms ND (4/00) |
Vion Pharmaceuticals Inc. (VION) | National Cancer Institute [Steven Rosenberg] | Cooperative research and development agreement | Evaluation of Vion's genetically altered anticancer Salmonella vectors (TAPET) | Vion and NCI signed a letter of intent for a five-year agreement under which Vion will provide Rosenberg's lab with a variety of TAPET vectors for further evaluation; in addition, Rosenberg is directing a Phase I clinical trial (3/00) |
Viragen Inc. (AMEX:VRA) | National Aeronautics and Space Adminstration | Space Act agreement | Use of NASA's bioreactors, which simulate low-gravity environments, to enhance production of interferon | Initial work will determine utility of approach, which could have applications in producing a spectrum of biologics, including antibodies (6/00) |
Xtrana* | U.S. Department of Defense | Contract development | Xtrana will develop a field-usable, nucleic acid-based test to detect coli-form bacteria in water; test is for lacZ gene in coliform bacteria and the uidA gene in E. coli | ND (4/00) |
Zycos Inc.* | The Centre for Applied Microbiology & Research (UK) | License | Zycos licensed patents for the development of polymer-based drug delivery systems | Zycos gains exclusive worldwide rights to the technology (5/00) |
Notes: |
||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-The-Counter Bulletin Board; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; SSE = Swedish Stock Exchange |
||||
Unless otherwise noted, the stock symbols listed are on the Nasdaq market. |
||||
* Privately held company |
||||
ND = Not disclosed. |
||||